Latest Stories
Featured
Gilead to Acquire Arcellx for $7.8B, Consolidating Control of BCMA CAR-T Program
EXCERPT: Gilead is acquiring Arcellx outright for $7.8 billion, bringing the BCMA-directed CAR-T therapy anitocabtagene autoleucel fully under Gilead’s Kite unit. The deal reflects continued big pharma confidence in cell
ADA & Immunogenicity
Why ELISA Alone Isn’t Enough for Host Cell Protein Testing
EXCERPT: Most labs run ELISA for residual host cell protein — but ELISA only tells you how much is there, not what it is. That distinction matters more than most
My Picks
Charles River Sells CDMO and Discovery Businesses — A Structural Shift in the CRO Landscape
EXCERPT: Charles River is divesting its manufacturing business to GI Partners and its discovery assets to IQVIA. The move reshapes the competitive landscape for CROs and CDMOs supporting early and
ADCs
AAV Contaminants Found in Liver Biopsy After Gene Therapy Infusion — A Manufacturing Wake-Up Call
EXCERPT: A Nature Medicine study found manufacturing plasmid sequences and incomplete helper virus genomes in liver tissue from a patient who developed acute liver failure after AAV therapy. The implications
My Picks
Eli Lilly Acquires Orna Therapeutics for Up to $2.4B, Betting on Circular RNA
EXCERPT: Lilly’s acquisition of Orna Therapeutics brings circular RNA and LNP delivery technology into one of pharma’s largest genetic medicine pipelines. The deal signals serious commercial interest in circRNA as